Skip to main content
. 2011 Oct;179(4):1638–1644. doi: 10.1016/j.ajpath.2011.06.020

Figure 2.

Figure 2

Correlation between EGFR expression and gene amplification. A total of 750 WHO grade II to IV gliomas were prospectively immunostained for EGFR and tested for gene amplification by FISH (see Materials and Methods). A: In all gliomas, the rate of EGFR amplification increased with increasing EGFR staining intensity. *P < 0.001 versus all other groups. B: Adjusting for WHO grade and morphologic subtype, the highest rates of EGFR amplification were seen in grades III and IV astrocytomas with strong EGFR expression. *P < 0.05 versus all negative and weak tumors; **P < 0.05 versus all but strong grade III astrocytoma (G3 astro). C: The risk of EGFR amplification (amp) was nearly nonexistent in all gliomas with negative (neg) or weak EGFR immunostaining, including GBMs. P < 0.0001. D: Specifically in non-GBM gliomas (in which EGFR amplification might change the diagnosis), there was a greatly increased risk of amplification if the tumor was moderately (mod) or strongly immunopositive for EGFR, although the rate was still only 14%. P < 0.0001.